Sanatio Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 16-11-2024
- Satisfied Charges ₹ 5.50 M
as on 16-11-2024
- Revenue 89.43%
(FY 2023)
- Profit 197.70%
(FY 2023)
- Ebitda 170.72%
(FY 2023)
- Net Worth 87.91%
(FY 2023)
- Total Assets 71.82%
(FY 2023)
About Sanatio Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹5.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pramod Singh and Birendrakumar Yadav serve as directors at the Company.
- CIN/LLPIN
U74120MH2016PTC271652
- Company No.
271652
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sanatio Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Singh  | Director | 24-Apr-2023 | Current |
| Birendrakumar Yadav | Director | 04-Jan-2016 | Current |
Financial Performance and Corporate Structure Insights of Sanatio Pharmaceuticals.
Sanatio Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 89.43% increase. The company also saw a substantial improvement in profitability, with a 197.7% increase in profit. The company's net worth Soared by an impressive increase of 87.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanatio Pharmaceuticals?
In 2023, Sanatio Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Apr 2021 | ₹5.00 M | Open |
Others Creation Date: 22 Feb 2019 | ₹5.50 M | Satisfied |
How Many Employees Work at Sanatio Pharmaceuticals?
Unlock and access historical data on people associated with Sanatio Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanatio Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanatio Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
